Biolife Sciences (Biolife Sciences) Debt-to-Equity : -6.82 (As of May. 2008)

View and export this data going back to 2005. Start your Free Trial

What is Biolife Sciences Debt-to-Equity?

Biolife Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in May. 2008 was $2.44 Mil. Biolife Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in May. 2008 was $0.42 Mil. Biolife Sciences's Total Stockholders Equity for the quarter that ended in May. 2008 was $-0.42 Mil. Biolife Sciences's debt to equity for the quarter that ended in May. 2008 was -6.82.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Biolife Sciences's Debt-to-Equity or its related term are showing as below:

BLFE's Debt-to-Equity is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 0.22
* Ranked among companies with meaningful Debt-to-Equity only.

Biolife Sciences Debt-to-Equity Historical Data

The historical data trend for Biolife Sciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biolife Sciences Debt-to-Equity Chart

Biolife Sciences Annual Data

Trend

Nov04

Nov05

Nov06

Nov07

Debt-to-Equity

0.24

4.98

10.53

44.33

Biolife Sciences Quarterly Data
	Feb05	May05	Aug05	Nov05	Feb06	May06	Aug06	Nov06	Feb07	May07	Aug07	Nov07	Feb08	May08
Debt-to-Equity	Get a 7-Day Free Trial									12.51	11.32	44.33	-12.34	-6.82

Competitive Comparison of Biolife Sciences's Debt-to-Equity

For the Medical Instruments & Supplies subindustry, Biolife Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biolife Sciences's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biolife Sciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Biolife Sciences's Debt-to-Equity falls into.

Biolife Sciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Biolife Sciences's Debt to Equity Ratio for the fiscal year that ended in Nov. 2007 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.454	+	0.206)	/	0.06
	=	44.33

Biolife Sciences's Debt to Equity Ratio for the quarter that ended in May. 2008 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.437	+	0.421)	/	-0.419
	=	-6.82

Biolife Sciences (OTCPK:BLFE) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Biolife Sciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Biolife Sciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Biolife Sciences (Biolife Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biolife Sciences Inc (OTCPK:BLFE) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

2831 Street Rose Parkway, No. 200, Henderson, NV, USA, 89052

Website

https://www.biolifesciences.com

Biolife Sciences Inc is a commercialization accelerator, licensor and developer of innovative and disruptive technologies for the healthcare, beauty and food and beverage industry sectors. The company's technologies include antimicrobial copper air filters and copper-infused textiles. Its revenues are primarily generated from the sale of sanitation products.

Executives

Arthur Viola

director, 10 percent owner, officer: CEO

Biolife Sciences (Biolife Sciences) Headlines

From GuruFocus

Rhino Novi Announces Name Change and New CEO

By Marketwired Marketwired • 09-15-2020